# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE

Addition of seven specific individual allergens to a cleared device (six recombinant and one purified native allergens).

# C. Measurand:

Seven new allergen-specific IgE analytes (6 recombinant and 1 native allergen): rBet v 2, (A127 Birch pollen, Betula verrucosa); rMal d 1 (A464 Apple, Malus domestica); rPru av 1, (A597 Cherry, Prunus avium); rPru av 3, (A599 Cherry, Prunus avium); rPru av 4 (A600 Cherry, Prunus avium); n Pru p 3, (A603 Peach, Prunus persica); rMal d 4, (A796 Apple, Malus domestica).

# G. Regulatory Information:

Regulation section: 21 CFR $\$ 866.5750$ , Radioallergosorbent (RAST) immunological test system

2. Classification: Class II

Product code: DHB - System, Test, Radioallergosorbent (RAST), Immunological

4. Panel: Immunology (82)

# H. Intended Use:

1. Intended use(s):

The IMMULITE 3gAllergy™ Specific IgE Universal kit is for in vitro diagnostic use with the IMMULITE 2000 Analyzer – for the quantitative measurement of allergenspecific IgE in human serum, as an aid in the clinical diagnosis of IgE-mediated allergic disorders. The test results are to be used in conjunction with clinical findings and other laboratory tests.

2. Indication(s) for use: Same as Intended Use

3. Special conditions for use statement(s): For prescription only

4. Special instrument requirements: IMMULITE 2000 Analyzer (k970227)

# I. Device Description:

Each device contains the following:

3gAllergy™ specific IgE bead pack (3 packs of 200 beads coated with anti-ligand) Specific IgE reagent wedge: $3 0 ~ \mathrm { m L }$ alkaline phosphatase (bovine calf intestine) conjugated to monoclonal murine anti-human IgE antibody in a human/nonhuman serum buffer matrix (equally dispensed in 1 wedge with B & C chambers)   
· Specific IgE adjustors: low and high (2 vials, $2 \mathrm { m L }$ each) of human IgE in a nonhuman serum matrix with preservative   
· Specific IgE adjustor antibody: 2 tubes, $2 . 7 5 \mathrm { m L }$ each) ready-to-use ligand-labeled polyclonal goat anti-human IgE antibody with preservative   
· Specific IgE universal kit controls: (2 vials, $2 \mathrm { m L }$ each) human IgE in a nonhuman sample matrix with preservative Specific IgE control antibody: (2 tubes, $2 . 7 5 \mathrm { m L }$ each) ready to use ligand-labeled polyclonal goat anti-human IgE antibody with preservative.

Kit components supplied separately:

3gAllergy™ specific IgE sample diluent (concentrated ready to use 1 vial, $2 5 ~ \mathrm { m L }$ ); chemiluminiscent substrate Probe wash; probe cleaning kit Disposable reaction tubes Bar coded allergen holder wedges serially coded 1-33; 34 -66; 67-99   
· Allergen tube caps and tube septa.

# J. Substantial Equivalence Information:

1. Predicate device name(s) and 510(k) number(s):

# IMMULITE $^ \mathrm { \textregistered }$ 2000 3gAllergy™ Specific IgE, k112523

3. Comparison with predicate:

<table><tr><td colspan="3" rowspan="1">Similarities</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">Device</td><td colspan="1" rowspan="1">Predicate</td></tr><tr><td colspan="1" rowspan="1">Intended use</td><td colspan="1" rowspan="1">The IMMULITE 3gAllergyTSpecific IgE Universal kit isfor in vitro diagnostic use withthe IMMULITE 2000Analyzer  for the quantitativemeasurement of allergen-specific IgE in human serum,as an aid in the clinicaldiagnosis of IgE-mediatedallergic disorders. The testresults are to be used inconjunction with clinicalfindings and other laboratorytests.</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Technology</td><td colspan="1" rowspan="1">Chemiluminescence</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Calibrators</td><td colspan="1" rowspan="1">Eight</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Controls</td><td colspan="1" rowspan="1">Specific IgE and Antibody andSpecific IgE UniversalControls</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Sample type</td><td colspan="1" rowspan="1">Serum</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Sample volume</td><td colspan="1" rowspan="1">50 μL</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Detection Antibody</td><td colspan="1" rowspan="1">Monoclonal murine anti-human IgE conjugated toalkaline phosphatase</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Process time</td><td colspan="1" rowspan="1">65 minutes</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Incubation temperature</td><td colspan="1" rowspan="1">37°C</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Result Interpretation</td><td colspan="1" rowspan="1">Quantitative values in kU/L;Interpretation of class resultsfor two scoring systems:Standard and Extendedstandard</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="3" rowspan="1">Differences</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">Device</td><td colspan="1" rowspan="1">Predicate</td></tr><tr><td colspan="1" rowspan="1">Total number of Allergens</td><td colspan="1" rowspan="1">Seven</td><td colspan="1" rowspan="1">Five</td></tr><tr><td colspan="1" rowspan="1">Types of SpecificAllergens</td><td colspan="1" rowspan="1">rBet v 2, (A127 Birchpollen, Betula verrucosa);rMal d 1 (A464 Apple,Malus domestica); rPru av1, (A597 Cherry, Prunusavium); rPru av 3, (A599Cherry, Prunus avium); rPruav 4 (A600 Cherry, Prunusavium); n Pru p 3, (A603Peach, Prunus persica);rMal d 4, (A796 Apple,Malus domestica).</td><td colspan="1" rowspan="1">nBet v 1 (A89: Birch Tree),nOle e 1 (A482 : OliveTree), nArt v 1 (A753:Mugwort weed), Cat SerumAlbumin (E220), and DogSerum Albumin (E221)</td></tr><tr><td colspan="1" rowspan="1">Allergen source</td><td colspan="1" rowspan="1">Allergenic proteinsexpressed by recombinanttechniques or purified fromnative sources</td><td colspan="1" rowspan="1">Whole allergen extracts orallergenic proteins purifiedfrom native sources only</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

CLSI I/LA 20-A2: Analytical Performance Characteristics and Clinical Utility of   
Immunological Assays for IgE Antibodies   
CLSI EP5-A2: Evaluation of Precision Performance of Quantitative Methods; Approved Guideline – Second Edition   
CLSI EP17-A: Protocols for Determination of Limits of Detection and Limit of Quantitation; Approved Guideline

# L. Test Principle:

The assay is a solid-phase, two-step, chemiluminiscent immunoassay that uses liquid phase kinetics in a bead format. The allergens are covalently bound to a soluble polymer/copolymer matrix, which is labeled with a ligand. The assay specific antibody is labeled with alkaline phosphatase. The use of an amino acid co-polymer amplifies the amount of allergen that the matrix can support. The chemiluminiscent detection system is a phosphatase ester of stabilized dioxatane. Cleavage of the phosphate ester by alkaline phosphatase results in the decomposition of dioxatane and the emission of photons, which are quantified by a luminometer.

# M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility:

Reproducibility of the assay was assessed by testing four positive samples (with one sample close to cut-off) and one negative control sample of each allergen: rBet v 2, (A127 Birch pollen); rMal d 1 (A464 Apple); rPru av 1, (A597 Cherry); rPru av 3, (A599 Cherry); rPru av 4 (A600 Cherry); n Pru p 3, (A603 Peach); rMal d 4, (A796 Apple) in duplicate twice a day for 20 different days $( \mathtt { n } = 8 0$ ).

The sponsor’s acceptance criterion for the negative sample was the average dose level must be ${ < } 0 . 1 0 \mathrm { k U / L }$ ; all negative sample mean results were within the acceptance criterion. The positive samples acceptance criterion was $\leq 1 5 \%$ CV for both intraassay and total precision. All positive sample mean results were within the acceptance criterion. Three allergen lots were tested for each allergen; representative data from one lot is shown below for the positive samples. The intra-assay, interassay and total $\% \mathrm { C V }$ ranges were from $3 . 0 9 \%$ to $7 . 9 6 \%$ ; $5 . 4 0 \%$ to $1 1 . 4 5 \%$ ; and $6 . 8 0 \%$ to $1 4 . 6 0 \%$ respectively (see tables below).

rBet v 2, (A127 Birch pollen)   

<table><tr><td rowspan=2 colspan=1>Sample</td><td rowspan=2 colspan=1>Mean(kU/L)</td><td rowspan=1 colspan=2>Intra-assay</td><td rowspan=1 colspan=2>Inter-assay</td><td rowspan=2 colspan=1>Total% CV</td></tr><tr><td rowspan=1 colspan=1>SD(kU/L)</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD(kU/L)</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>Positive #1</td><td rowspan=1 colspan=1>0.58</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>4.11</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>6.53</td><td rowspan=1 colspan=1>13.74</td></tr><tr><td rowspan=1 colspan=1>Positive #2</td><td rowspan=1 colspan=1>1.59</td><td rowspan=1 colspan=1>0.06</td><td rowspan=1 colspan=1>3.42</td><td rowspan=1 colspan=1>0.09</td><td rowspan=1 colspan=1>5.75</td><td rowspan=1 colspan=1>10.72</td></tr><tr><td rowspan=1 colspan=1>Positive #3</td><td rowspan=1 colspan=1>7.99</td><td rowspan=1 colspan=1>0.28</td><td rowspan=1 colspan=1>3.53</td><td rowspan=1 colspan=1>0.48</td><td rowspan=1 colspan=1>6.04</td><td rowspan=1 colspan=1>10.77</td></tr><tr><td rowspan=1 colspan=1>Positive #4</td><td rowspan=1 colspan=1>0.37</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>7.35</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>7.45</td><td rowspan=1 colspan=1>8.03</td></tr></table>

rMal d 1 (A464 Apple)   

<table><tr><td rowspan=2 colspan=1>Sample</td><td rowspan=2 colspan=1>Mean(kU/L)</td><td rowspan=1 colspan=2>Intra-assay</td><td rowspan=1 colspan=2>Inter-assay</td><td rowspan=2 colspan=1>Total %CV</td></tr><tr><td rowspan=1 colspan=1>SD(kU/L)</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD(kU/L)</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>Positive #1</td><td rowspan=1 colspan=1>0.57</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>4.64</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>7.47</td><td rowspan=1 colspan=1>13.84</td></tr><tr><td rowspan=1 colspan=1>Positive #2</td><td rowspan=1 colspan=1>2.59</td><td rowspan=1 colspan=1>0.11</td><td rowspan=1 colspan=1>4.30</td><td rowspan=1 colspan=1>0.18</td><td rowspan=1 colspan=1>7.04</td><td rowspan=1 colspan=1>16.61</td></tr><tr><td rowspan=1 colspan=1>Positive #3</td><td rowspan=1 colspan=1>5.58</td><td rowspan=1 colspan=1>0.23</td><td rowspan=1 colspan=1>4.20</td><td rowspan=1 colspan=1>0.38</td><td rowspan=1 colspan=1>6.76</td><td rowspan=1 colspan=1>12.30</td></tr><tr><td rowspan=1 colspan=1>Positive #4</td><td rowspan=1 colspan=1>0.36</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>7.96</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>8.67</td><td rowspan=1 colspan=1>9.48</td></tr></table>

rPru av 1, (A597 Cherry)   

<table><tr><td rowspan=2 colspan=1>Sample</td><td rowspan=2 colspan=1>Mean(kU/L)</td><td rowspan=1 colspan=2>Intra-assay</td><td rowspan=1 colspan=2>Inter-assay</td><td rowspan=2 colspan=1>Total% CV</td></tr><tr><td rowspan=1 colspan=1>SD(kU/L)</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD(kU/L)</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>Positive #1</td><td rowspan=1 colspan=1>0.61</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>5.22</td><td rowspan=1 colspan=1>0.05</td><td rowspan=1 colspan=1>7.72</td><td rowspan=1 colspan=1>10.57</td></tr><tr><td rowspan=1 colspan=1>Positive #2</td><td rowspan=1 colspan=1>2.48</td><td rowspan=1 colspan=1>0.09</td><td rowspan=1 colspan=1>3.75</td><td rowspan=1 colspan=1>0.25</td><td rowspan=1 colspan=1>10.11</td><td rowspan=1 colspan=1>11.85</td></tr><tr><td rowspan=1 colspan=1>Positive #3</td><td rowspan=1 colspan=1>6.97</td><td rowspan=1 colspan=1>0.28</td><td rowspan=1 colspan=1>3.99</td><td rowspan=1 colspan=1>0.47</td><td rowspan=1 colspan=1>6.76</td><td rowspan=1 colspan=1>13.88</td></tr><tr><td rowspan=1 colspan=1>Positive #4</td><td rowspan=1 colspan=1>0.38</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>6.25</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>7.13</td><td rowspan=1 colspan=1>14.60</td></tr></table>

rPru av 3, (A599 Cherry)   

<table><tr><td rowspan=2 colspan=1>Sample</td><td rowspan=2 colspan=1>Mean(kU/L)</td><td rowspan=1 colspan=2>Intra-assay</td><td rowspan=1 colspan=2>Inter-assay</td><td rowspan=2 colspan=1>Total% CV</td></tr><tr><td rowspan=1 colspan=1>SD(kU/L)</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD(kU/L)</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>Positive #1</td><td rowspan=1 colspan=1>0.56</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>5.04</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>6.74</td><td rowspan=1 colspan=1>10.32</td></tr><tr><td rowspan=1 colspan=1>Positive #2</td><td rowspan=1 colspan=1>1.45</td><td rowspan=1 colspan=1>0.05</td><td rowspan=1 colspan=1>3.45</td><td rowspan=1 colspan=1>0.09</td><td rowspan=1 colspan=1>5.99</td><td rowspan=1 colspan=1>11.28</td></tr><tr><td rowspan=1 colspan=1>Positive #3</td><td rowspan=1 colspan=1>9.14</td><td rowspan=1 colspan=1>0.32</td><td rowspan=1 colspan=1>3.50</td><td rowspan=1 colspan=1>0.55</td><td rowspan=1 colspan=1>6.04</td><td rowspan=1 colspan=1>11.18</td></tr><tr><td rowspan=1 colspan=1>Positive #4</td><td rowspan=1 colspan=1>0.39</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>5.74</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>6.42</td><td rowspan=1 colspan=1>6.80</td></tr></table>

rPru av 4 (A600 Cherry)   

<table><tr><td rowspan=2 colspan=1>Sample</td><td rowspan=2 colspan=1>Mean(kU/L)</td><td rowspan=1 colspan=2>Intra-assay</td><td rowspan=1 colspan=2>Inter-assay</td><td rowspan=2 colspan=1>Total% CV</td></tr><tr><td rowspan=1 colspan=1>SD(kU/L)</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD(kU/L)</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>Positive #1</td><td rowspan=1 colspan=1>0.64</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>3.65</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>5.91</td><td rowspan=1 colspan=1>7.06</td></tr><tr><td rowspan=1 colspan=1>Positive #2</td><td rowspan=1 colspan=1>1.30</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>3.23</td><td rowspan=1 colspan=1>0.15</td><td rowspan=1 colspan=1>11.45</td><td rowspan=1 colspan=1>12.50</td></tr><tr><td rowspan=1 colspan=1>Positive #3</td><td rowspan=1 colspan=1>8.55</td><td rowspan=1 colspan=1>0.34</td><td rowspan=1 colspan=1>4.00</td><td rowspan=1 colspan=1>0.59</td><td rowspan=1 colspan=1>6.88</td><td rowspan=1 colspan=1>11.14</td></tr><tr><td rowspan=1 colspan=1>Positive #4</td><td rowspan=1 colspan=1>0.42</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>6.26</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>7.06</td><td rowspan=1 colspan=1>8.37</td></tr></table>

n Pru p 3, (A603 Peach)   

<table><tr><td rowspan=2 colspan=1>Sample</td><td rowspan=2 colspan=1>Mean(kU/L)</td><td rowspan=1 colspan=2>Intra-assay</td><td rowspan=1 colspan=2>Inter-assay</td><td rowspan=2 colspan=1>Total% CV</td></tr><tr><td rowspan=1 colspan=1>SD(kU/L)</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD(kU/L)</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>Positive #1</td><td rowspan=1 colspan=1>0.58</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>3.87</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>6.15</td><td rowspan=1 colspan=1>8.15</td></tr><tr><td rowspan=1 colspan=1>Positive #2</td><td rowspan=1 colspan=1>1.64</td><td rowspan=1 colspan=1>0.05</td><td rowspan=1 colspan=1>3.27</td><td rowspan=1 colspan=1>0.10</td><td rowspan=1 colspan=1>6.07</td><td rowspan=1 colspan=1>7.95*</td></tr><tr><td rowspan=1 colspan=1>Positive #3</td><td rowspan=1 colspan=1>9.32</td><td rowspan=1 colspan=1>0.29</td><td rowspan=1 colspan=1>3.09</td><td rowspan=1 colspan=1>0.69</td><td rowspan=1 colspan=1>7.39</td><td rowspan=1 colspan=1>7.80</td></tr><tr><td rowspan=1 colspan=1>Positive #4</td><td rowspan=1 colspan=1>0.39</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>5.52</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>6.49</td><td rowspan=1 colspan=1>14.03</td></tr></table>

\*Outliers detected on Day 10, Runs 1, 2; Replicates 1, 2 due to operator error; No outliers used in calculation

rMal d 4, (A796 Apple).   

<table><tr><td rowspan=2 colspan=1>Sample</td><td rowspan=2 colspan=1>Mean(kU/L)</td><td rowspan=1 colspan=2>Intra-assay</td><td rowspan=1 colspan=2>Inter-assay</td><td rowspan=2 colspan=1>Total% CV</td></tr><tr><td rowspan=1 colspan=1>SD(kU/L)</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD(kU/L)</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>Positive #1</td><td rowspan=1 colspan=1>0.65</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>3.76</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>5.58</td><td rowspan=1 colspan=1>7.09</td></tr><tr><td rowspan=1 colspan=1>Positive #2</td><td rowspan=1 colspan=1>1.65</td><td rowspan=1 colspan=1>0.05</td><td rowspan=1 colspan=1>3.30</td><td rowspan=1 colspan=1>0.10</td><td rowspan=1 colspan=1>5.79</td><td rowspan=1 colspan=1>9.24</td></tr><tr><td rowspan=1 colspan=1>Positive #3</td><td rowspan=1 colspan=1>7.44</td><td rowspan=1 colspan=1>0.24</td><td rowspan=1 colspan=1>3.17</td><td rowspan=1 colspan=1>0.40</td><td rowspan=1 colspan=1>5.40</td><td rowspan=1 colspan=1>7.68</td></tr><tr><td rowspan=1 colspan=1>Positive #4</td><td rowspan=1 colspan=1>0.35</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>7.41</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>8.56</td><td rowspan=1 colspan=1>8.80</td></tr></table>

# Lot to lot imprecision:

The three tested lots were analyzed for lot-to-lot precision using four positive samples (with one sample close to the cut-off) and one negative sample. Between-lot withinrun imprecision ranged from $4 . 4 3 \%$ to $1 3 . 6 0 \%$ and the total imprecision ranged from $5 . 8 3 \%$ to $1 5 . 7 5 \%$ . All three lots were within the sponsor’s claimed acceptable criterion of $\leq 2 0 \%$ CV.

# b. Linearity/assay reportable range:

Linearity studies: For each allergen, two clinical samples were diluted in 2-fold serial dilutions to 5 levels. The undiluted (neat) and diluted samples were tested with the specific allergen to demonstrate linearity at concentrations within the assay limits. Regression statistics for each allergen comparing the observed results to expected results of the representative data from first sample are presented below:

<table><tr><td rowspan=1 colspan=1>Allergen</td><td rowspan=1 colspan=1>RegressionEquation</td><td rowspan=1 colspan=1>Slope95% CI</td><td rowspan=1 colspan=1>Intercept95% CI</td><td rowspan=1 colspan=1>r</td></tr><tr><td rowspan=1 colspan=1>rBet v 2</td><td rowspan=1 colspan=1>y = 1.00x + 0.01</td><td rowspan=1 colspan=1>0.95 to 1.05</td><td rowspan=1 colspan=1>-0.05 to 0.06</td><td rowspan=1 colspan=1>0.998</td></tr><tr><td rowspan=1 colspan=1>rMal d 1</td><td rowspan=1 colspan=1>y= 1.01x +0.09</td><td rowspan=1 colspan=1>0.99 to 1.04</td><td rowspan=1 colspan=1>0.002 to 0.18</td><td rowspan=1 colspan=1>1.000</td></tr><tr><td rowspan=1 colspan=1>rPru av 1</td><td rowspan=1 colspan=1>y=1.05x +-0.03</td><td rowspan=1 colspan=1>1.01 to 1.08</td><td rowspan=1 colspan=1>-0.05 to -0.01</td><td rowspan=1 colspan=1>0.999</td></tr><tr><td rowspan=1 colspan=1>rPru av 3</td><td rowspan=1 colspan=1>y = 1.00x +(-0.05</td><td rowspan=1 colspan=1>0.98 to 1.03</td><td rowspan=1 colspan=1>0.02 to 0.07</td><td rowspan=1 colspan=1>0.999</td></tr><tr><td rowspan=1 colspan=1>rPru av 4</td><td rowspan=1 colspan=1>y= 0.97x+-0.02</td><td rowspan=1 colspan=1>0.94 to 0.99</td><td rowspan=1 colspan=1>-0.003 to 0.04</td><td rowspan=1 colspan=1>1.000</td></tr><tr><td rowspan=1 colspan=1>n Pru p 3</td><td rowspan=1 colspan=1>y = 0.99x + 0.05</td><td rowspan=1 colspan=1>0.96 to 1.02</td><td rowspan=1 colspan=1>-0.02 to 0.08</td><td rowspan=1 colspan=1>0.999</td></tr><tr><td rowspan=1 colspan=1>rMal d 4</td><td rowspan=1 colspan=1>y= 0.96x + 0.04</td><td rowspan=1 colspan=1>0.92 to 1.00</td><td rowspan=1 colspan=1>0.01 to 1.00</td><td rowspan=1 colspan=1>0.999</td></tr></table>

The IMMULITE 2000 Calibrator assay range: $0 . 1 \mathrm { ~ - ~ } 1 0 0 \mathrm { k U / L }$ .

c. Traceability, Stability, Expected values (controls, calibrators, or methods):

Traceability: The calibrators and controls are traceable to the WHO $2 ^ { \mathrm { n d } }$ IRP 75/502 reference standard for human IgE.

Stability:

Allergen stability: Accelerated allergen stability testing ( $1 5 { - } 2 5 ^ { \circ } \mathrm { C }$ for 60 days at 1, 4, 8, 15, 30, and 60 day intervals; other assay kit components stored at recommended temperature $2 { - } 8 ^ { \circ } \mathrm { C }$ ). Testing was performed on three positive samples and one negative sample on two lots. The accelerated study supports a two year shelf-life stability claim. Real-time stability is on-going for all 7 new allergen on three lots with three positive (high: 3.5; moderate 0.7-3.49 and low near the cut-off 0.35-0.69 kU/L) and one negative samples.

# On-board/ open-vial stability:

On-board stability testing was performed on three positive samples and one negative sample for 91 days at $2 { - } 8 ^ { \circ } \mathrm { C }$ (at 1, 7, 14, 21, 32, 46, 60, 75 and $9 0 +$ day intervals) for each individual specific allergen on three lots. Stability studies support the 90 day on-board stability claim.

Open-vial stability testing was performed on three positive samples and one negative sample for 180 days at $2 { - } 8 ^ { \circ } \mathrm { C }$ (at 1, 30, 60, 90, 180, and on-going for 360, 390, 540, 720 and 750 day intervals) for each individual specific allergen on three lots. Stability studies support the 180 day on-board stability claim.

# d. Detection limit:

Limit of Blank (LoB): Four blank samples (no analyte) were tested in replicates of two, with one run per day, over five days, using two instruments and three lots of allergen. A total of 80 data points were collected for each allergen lot. The Limit of Blank (highest value expected for a sample with no analyte), determined in accordance with CLSI EP17-A, is $0 . 0 6 \mathrm { { k U / L } }$ for rPru av 4 (A600 Cherry) and $0 . 0 3 \mathrm { { k U / L } }$ for the other six allergens.

Limit of Detection (LoD):

Four low positive samples were tested using 3 allergen lots over 5 days, at one run per day, 2 replicates per run to estimate the LoD. Two instruments were used to collect a total of 60 data points for each new allergen. The Limit of Detection (lowest detectable concentration), determined in accordance with CLSI EP-17-A is ${ \underline { { < 0 . 1 0 \mathrm { k U / L } } } }$ for all seven allergens.

# e. Analytical specificity:

(i) Inhibition studies - Related inhibitor

Specificity of each allergen was verified through competitive inhibition testing using a single serum sample or a serum pool. A negative sample was used to measure the background response.

To initiate the inhibition experiment, a minimum of 5 levels of 5-fold diluted inhibitor extract were mixed with sample or pool at a ratio of 1:1 to achieve final inhibitor concentrations of $5 0 ~ \mu \mathrm { g / m L }$ and lower. The inhibitor/sample mixtures were incubated at room temperature $( 1 5 . 2 8 ^ { \circ } \mathrm { C } )$ for 1 hour allowing the immunological reaction to occur. Each sample mixture containing the inhibitor extract and the appropriate controls were assayed with 1 lot of each allergen. The percent $( \% )$ inhibition was calculated according to the following formula:

$$
[ ( \mathrm { C } - \mathrm { A } / \mathrm { C } ) ] \mathrm { ~ x ~ } 1 0 0
$$

where:

$\mathrm { C } =$ mean response of the positive control (positive sample – negative sample) $\mathbf { A } =$ mean response of sample with inhibitor extract

The data demonstrated that the allergens tested are inhibited by the relevant inhibitor extract in a concentration dependent fashion and are specific for the targeted allergen. The target $\%$ inhibition is $50 \%$ at the highest inhibitor concentration tested. All seven allergens met the target $\%$ inhibition. These results indicate specificity of rBet v 2, (A127 Birch pollen); rMal d 1 (A464 Apple); rPru av 1, (A597 Cherry); rPru av 3, (A599 Cherry); rPru av 4 (A600

Cherry); n Pru p 3, (A603 Peach); rMal d 4, (A796 Apple) allergens.

(ii) Inhibition studies - Unrelated inhibitor

Additional inhibition studies were conducted to show that the specific allergens do not cross-react with unrelated allergens. Three irrelevant allergens, as well as any related components, were included as additional controls. The related components were other components of the parent allergen (if available) or another component from the same group. The final inhibitor concentrations of the additional inhibitors ranged from $5 0 0 ~ \mu \mathrm { g / m L }$ to $1 2 5 0 ~ \mu \mathrm { g / m L }$ , determined as 10x the concentration needed to achieve ${ \sim } 1 0 0 \%$ inhibition on its own allergen device. The same incubation procedure and calculation method were used as described above with relevant inhibitor procedure. The sponsor’s acceptance criterion is that the irrelevant allergen controls should demonstrate less than $1 5 \%$ inhibition was met for all seven allergens.

f. Assay cut-off: Not applicable.

2. Comparison studies:

a. Method comparison with predicate device: Refer to Clinical studies   
$b$ . Matrix comparison: Not applicable. Serum is the only sample matrix.

3. Clinical studies:

# a. Clinical Sensitivity and Specificity:

Clinical performance of the IMMULITE® 2000 3gAllergy Specific IgE assay for rBet v 2, (A127 Birch pollen); rMal d 1 (A464 Apple); rPru av 1, (A597 Cherry); rPru av 3, (A599 Cherry); rPru av 4 (A600 Cherry); n Pru p 3, (A603 Peach); rMal d 4, (A796 Apple) allergens was demonstrated by testing samples from non-atopic and atopic individuals.

Atopic patients were selected from patients who had clinical documentation of allergy to specific allergen(s) or allergen group of interest and/or positive skin prick/ scratch test to specific allergen(s) of interest evaluated as $^ { 2 + }$ or greater. Information on the skin test allergen extracts (crude or purified) was not documented. Non-atopic patients were clinically known non-allergenic or total IgE $< 1 3 0 ~ \mathrm { n g / m L }$ or $5 4 ~ \mathrm { I U / m L }$ $( 2 . 4 \mathrm { n g } = 1 \mathrm { I U } )$ ).

Comparison to clinical diagnosis was performed on 187 samples for rBet v 2, (A127 Birch pollen); 171 Samples for rMal d 1 (A464 Apple); 154 Samples for rPru av 1, (A597 Cherry); 154 Samples for rPru av 3, (A599 Cherry); 154 Samples for rPru av

4 (A600 Cherry); 155 samples for n Pru p 3, (A603 Peach); and 171 Samples for rMal d 4, (A796 Apple).

Sensitivity and specificity of the new device, based on diagnosis of atopic status, are shown in the tables below (refer to tabulated literature support on allergens with low sensitivity/ low prevalence listed below):

<table><tr><td rowspan=2 colspan=2>Allergen: rBet v 2, (A127Birch pollen)</td><td rowspan=1 colspan=3>Clinical Diagnosis</td></tr><tr><td rowspan=1 colspan=1>Atopic</td><td rowspan=1 colspan=1>Non-atopic</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>IMMULITE2000</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>26</td></tr><tr><td rowspan=1 colspan=1>negative</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>116</td><td rowspan=1 colspan=1>161</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>70</td><td rowspan=1 colspan=1>117</td><td rowspan=1 colspan=1>187</td></tr></table>

Sensitivity: 35.7 % (25/70) (95% CI: 24.6 ‒ 48.1%) Specificity: $9 9 . 1 \%$ (116/117) (95% CI: 95.3 ‒ 100%)

<table><tr><td rowspan=2 colspan=2>Allergen: rMal d 1 (A464Apple)</td><td rowspan=1 colspan=3>Clinical Diagnosis</td></tr><tr><td rowspan=1 colspan=1>Atopic</td><td rowspan=1 colspan=1>Non-atopic</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>IMMULITE2000</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>51</td></tr><tr><td rowspan=1 colspan=1>negative</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>116</td><td rowspan=1 colspan=1>120</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>54</td><td rowspan=1 colspan=1>117</td><td rowspan=1 colspan=1>171</td></tr></table>

Sensitivity: $9 2 . 6 \%$ (50/54) (95% CI: 82.1 ‒ 97.9%) Specificity: $9 9 . 1 \%$ (116/1017) (97% CI: 95.3 ‒ 100%)

<table><tr><td rowspan=2 colspan=2>Allergen: rPru av 1,(A597 Cherry)</td><td rowspan=1 colspan=3>Clinical Diagnosis</td></tr><tr><td rowspan=1 colspan=1>Atopic</td><td rowspan=1 colspan=1>Non-atopic</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>IMMULITE2000</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>33</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>38</td></tr><tr><td rowspan=1 colspan=1>negative</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>112</td><td rowspan=1 colspan=1>116</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>37</td><td rowspan=1 colspan=1>117</td><td rowspan=1 colspan=1>154</td></tr></table>

Sensitivity: $89 . 2 \%$ (33/37) (95% CI: 74.6- 97.0%) Specificity: $9 5 . 7 \%$ (112/117) (95% CI: 90.3 ‒ 98.6?%)

<table><tr><td rowspan=2 colspan=2>Allergen: rPru av 3,(A599 Cherry)</td><td rowspan=1 colspan=3>Clinical Diagnosis</td></tr><tr><td rowspan=1 colspan=1>Atopic</td><td rowspan=1 colspan=1>Non-atopic</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>IMMULITE2000</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>10</td></tr><tr><td rowspan=1 colspan=1>negative</td><td rowspan=1 colspan=1>27</td><td rowspan=1 colspan=1>117</td><td rowspan=1 colspan=1>144</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>37</td><td rowspan=1 colspan=1>117</td><td rowspan=1 colspan=1>154</td></tr></table>

Sensitivity: $2 7 \%$ (10/37) (95% CI: 13.8 ‒ 44.1%) Specificity: $100 \%$ (117/117) (95% CI: 96.9 ‒ 100%)

<table><tr><td rowspan=2 colspan=2>Allergen: rPru av 4(A600 Cherry)</td><td rowspan=1 colspan=3>Clinical Diagnosis</td></tr><tr><td rowspan=1 colspan=1>Atopic</td><td rowspan=1 colspan=1>Non-atopic</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>IMMULITE2000</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>10</td></tr><tr><td rowspan=1 colspan=1>negative</td><td rowspan=1 colspan=1>28</td><td rowspan=1 colspan=1>116</td><td rowspan=1 colspan=1>144</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>37</td><td rowspan=1 colspan=1>117</td><td rowspan=1 colspan=1>154</td></tr></table>

Sensitivity: $2 4 . 3 \%$ (9/37) (95% CI: 11.8 ‒ 41.2%) Specificity: $9 9 . 1 \%$ (116/117) (95% CI: 95.3 ‒ 100%)

<table><tr><td rowspan=2 colspan=2>Allergen: n Pru p 3,(A603 Peach)</td><td rowspan=1 colspan=3>Clinical Diagnosis</td></tr><tr><td rowspan=1 colspan=1>Atopic</td><td rowspan=1 colspan=1>Non-atopic</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>IMMULITE2000</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>11</td></tr><tr><td rowspan=1 colspan=1>negative</td><td rowspan=1 colspan=1>27</td><td rowspan=1 colspan=1>117</td><td rowspan=1 colspan=1>144</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>38</td><td rowspan=1 colspan=1>117</td><td rowspan=1 colspan=1>155</td></tr></table>

Sensitivity: $2 8 . 9 \%$ (11/38) (95% CI: 15.4 ‒ 45.9%) Specificity: $100 \%$ (117/117) (95% CI: 96.9 ‒ 100%)

<table><tr><td rowspan=2 colspan=2>Allergen: rMal d 4,(A796 Apple)</td><td rowspan=1 colspan=3>Clinical Diagnosis</td></tr><tr><td rowspan=1 colspan=1>Atopic</td><td rowspan=1 colspan=1>Non-atopic</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>IMMULITE2000</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>16</td></tr><tr><td rowspan=1 colspan=1>negative</td><td rowspan=1 colspan=1>39</td><td rowspan=1 colspan=1>116</td><td rowspan=1 colspan=1>155</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>54</td><td rowspan=1 colspan=1>117</td><td rowspan=1 colspan=1>171</td></tr></table>

Sensitivity: $2 7 . 8 \%$ (15/34) (95% CI: 16.5 ‒ 41.6%) Specificity: $9 9 . 1 \%$ (116/117) (95% CI: 95.3 ‒ 100%)

Literature support was provided on allergens with low prevalence and low sensitivity as shown in the Table below:

<table><tr><td colspan="1" rowspan="1">SpecificAllergen% ClinicalSen./Spec.</td><td colspan="1" rowspan="1">Literature Citation(s)</td><td colspan="1" rowspan="1">Study UsedNative orRecombinantAllergen</td><td colspan="1" rowspan="1">Prevalence</td><td colspan="1" rowspan="1">ReportedSensitivity</td></tr><tr><td colspan="1" rowspan="1">A127 (rBet</td><td colspan="1" rowspan="1">Rossi RE, Monasterolo G., Monasterolo S. Detectionof specific IgE antibodies in the sera of patientsallergic to birch pollen using recombinant allergensBet v 1, Bet v 2, Bet v 4:evaluation of different IgEreactivity profiles. Allergy. 2003;58(9):929-32.</td><td colspan="1" rowspan="1">Native BirchRecombinantBet v 2</td><td colspan="1" rowspan="1">Among patientssuffering frompollinosis, 5-54%are sensitive tobirch pollen</td><td colspan="1" rowspan="1">Among birch-sensitive patients,45% had serumIgE antibodies torBet v 2</td></tr><tr><td colspan="1" rowspan="2">v 2),BirchPollen35.7% /99.1%</td><td colspan="1" rowspan="1">Scala E, Alessandri C, Bernardi ML, Ferrara R,Palazzo P, Pomponi D, et al. Cross-sectional surveyon immunoglobulin E reactivity in 23077 subjectsusing an allergenic molecule-based microarraydetection system. Clin Exp Allergy. 2010;40(6):911-21.</td><td colspan="1" rowspan="1">RecombinantBet v 2</td><td colspan="1" rowspan="1">Among subjectspositive to at leastone allergeniccomponent, 6%(986/16408) haddetectable IgElevels for rBet v 2</td><td colspan="1" rowspan="1">(not reported)</td></tr><tr><td colspan="1" rowspan="1">Karamloo F, Schmitz N, Scheurer S et al.Molecular cloning and characterization of a birchpollen minor allergen, Bet v 5, belonging to a family</td><td colspan="1" rowspan="1">RecombinantBet v 2</td><td colspan="1" rowspan="1">(not reported)</td><td colspan="1" rowspan="1">Among birch-sensitive patients,10-18% had</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">of isoflavone reductase-realted proteins. J AllergyClin Immunol. 1999;104: 991-9.</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">serum IgEantibodies to rBetv 2</td></tr><tr><td colspan="1" rowspan="2">A599 (rPruav 3),Cherry27.0% /100.0%</td><td colspan="1" rowspan="1">Eriksson NE, Moller C, Werner S, Magnusson J,Bengtsson U, Zolubas M. Self-reported foodhypersensitivity in Sweden, Denmark, Estonia,Lithuania, and Russia. J Investig Allergol ClinImmunol. 2004;14(1):70-9.</td><td colspan="1" rowspan="1">Native Cherry</td><td colspan="1" rowspan="1">Among 1,139subjects with foodallergies, 19%reported sensitivityto cherry</td><td colspan="1" rowspan="1">(not reported)</td></tr><tr><td colspan="1" rowspan="1">Ballmer-Weber B, Scheurer S, Fritsche P, Enrique E,Cistero-Bahima A, Haase T, et al.Component-resolved diagnosis with recombinantallergens in patients with cherry allergy. J AllergyClin Immunol. 2002; 110(1): 167-73.</td><td colspan="1" rowspan="1">RecombinantPru av 3</td><td colspan="1" rowspan="1">(not reported)</td><td colspan="1" rowspan="1">Among cherry-sensitive patients,4% were alsosensitized torPru av 3</td></tr><tr><td colspan="1" rowspan="3">A600 (rPruav 4),Cherry24.3% /99.1%</td><td colspan="1" rowspan="1">Eriksson NE, Moller C, Werner S, Magnusson J,Bengtsson U, Zolubas M. Self-reported foodhypersensitivity in Sweden, Denmark, Estonia,Lithuania, and Russia. J Investig Allergol ClinImmunol. 2004;14(1):70-9.</td><td colspan="1" rowspan="1">Native Cherry</td><td colspan="1" rowspan="1">Among 1,139subjects with foodallergies, 19%reported sensitivityto cherry</td><td colspan="1" rowspan="1">(not reported)</td></tr><tr><td colspan="1" rowspan="1">Scheurer S, Pastorello EA, Wangorsch A, Kastner M,Haustein D, Vieths S. Recombinantallergens Pru av 1 and Pru av 4 and a newly identifiedlipid transfer protein in the in vitro diagnosis ofcherry allergy. J Allergy Clin Immunol2001;107(4):724-31.</td><td colspan="1" rowspan="1">RecombinantPru av 4</td><td colspan="1" rowspan="1">(not reported)</td><td colspan="1" rowspan="1">Among cherry-sensitive patients,16% had serumIgE antibodies torPru av 4</td></tr><tr><td colspan="1" rowspan="1">Ballmer-Weber B, Scheurer S, Fritsche P, Enrique E,Cistero-Bahima A, Haase T, et al. Component-resolved diagnosis with recombinant allergens inpatients with cherry allergy. J Allergy Clin Immunol.2002;110(1):167-73.</td><td colspan="1" rowspan="1">RecombinantPru av 4</td><td colspan="1" rowspan="1">(not reported)</td><td colspan="1" rowspan="1">Among cherryand/or birchsensitive patients,17-30% were alsosensitized to rPruav 4</td></tr><tr><td colspan="1" rowspan="5">A603 (nPrup 3), Peach28.9% /100%</td><td colspan="1" rowspan="1">Eriksson NE, Moller C, Werner S, Magnusson J,Bengtsson U, Zolubas M. Self-reported foodhypersensitivity in Sweden, Denmark, Estonia,Lithuania, and Russia. J Investig Allergol ClinImmunol. 2004;14(1):70-9.</td><td colspan="1" rowspan="1">NativePeach</td><td colspan="1" rowspan="1">Among 1,139subjects with foodallergies, 29%reported sensitivityto peach</td><td colspan="1" rowspan="1">(not reported)</td></tr><tr><td colspan="1" rowspan="1">Barber D, de la Torre F, Feo F, Florido F, Guardia P,Moreno C, et al. Understanding patient sensitizationprofiles in cmplex pollen areas: a molecularepidemological study. Allergy. 2008;63: 1550-8.</td><td colspan="1" rowspan="1">RecombinantPru p 3</td><td colspan="1" rowspan="1">Among generalallergicpopulations, 13%reportedsensitization torPru p 3</td><td colspan="1" rowspan="1">(not reported)</td></tr><tr><td colspan="1" rowspan="1">Caimmi D, Barber D, Hoffmann-Sommergruber K,Amrane H, Bousquet P, Dhivert-Donnadieu H, et al.Understanding the molecular sensitization for Cypresspollen and peach in the Languedoc-Roussillon area.Allergy. 2013; 68: 249-51.</td><td colspan="1" rowspan="1">RecombinantPru p 3</td><td colspan="1" rowspan="1">(not reported)</td><td colspan="1" rowspan="1">Among 129patients sufferingfrom rhinitissymptoms, 7%were sensitized torPru p 3</td></tr><tr><td colspan="1" rowspan="1">Scala E, Alessandri C, Bernardi ML, Ferrara R,Palazzo P, Pomponi D, et al. Cross-sectional surveyon immunoglobulin E reactivity in 23077 subjectsusing an allergenic molecule-based microarraydetection system. Clin Exp Allergy. 2010;40(6):911-21.</td><td colspan="1" rowspan="1">NativePru p 3</td><td colspan="1" rowspan="1">Among subjectspositive to at leastone allergeniccomponent, 10%(1607/16408) haddetectable IgElevels for nPru p 3</td><td colspan="1" rowspan="1">(not reported)</td></tr><tr><td colspan="1" rowspan="1">Barber D, de la Torre F, Lombardero M, Antepara I,Colas C, et al. Component-resolved diagnosis of</td><td colspan="1" rowspan="1">NativePru p 3</td><td colspan="1" rowspan="1">Among generalallergic</td><td colspan="1" rowspan="1">(not reported)</td></tr><tr><td colspan="1" rowspan="3"></td><td colspan="1" rowspan="1">pollen allergy based on skin testing with profilin,polcalcin and lipid transfer protein pan-allergens. ClinExp Allergy. 2009;39:1764-73.</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">populations, 2-40% reportedsensitization tonPru p 3</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Rodriguez-Perez R, Fernandez-Rivas M, Gonzalez-Mancebo E, Sanchez-Monge R, Diaz-Perales A,Salcedo G. Peach profilin: cloning, heterologousexpression and cross-reactivity with Bet v 2. Allergy.58(7):635-640.</td><td colspan="1" rowspan="1">NativePru p 3</td><td colspan="1" rowspan="1">(not reported)</td><td colspan="1" rowspan="1">Among peachpositive subjects,4% were alsosensitized to nPrup3</td></tr><tr><td colspan="1" rowspan="1">Fernandez-Rivas M, Gonzalez-Mancebo E,Rodriguez-Perez R, Benito C, Sanchez-Monge R,Salcedo G, et al. Clinically relevant peach allergy isrelated to peach lipid transfer protein, Pru p 3, in theSpanish population. J Allergy Clin Immunol.2003;112(4):789-95.</td><td colspan="1" rowspan="1">NativePru p 3</td><td colspan="1" rowspan="1">(not reported)</td><td colspan="1" rowspan="1">Among peachpositive subjects,62% were alsosensitized to nPrup3</td></tr><tr><td colspan="1" rowspan="4">A796 (rMald 4); Apple27.8% /99.1%</td><td colspan="1" rowspan="1">Eriksson NE, Moller C, Werner S, Magnusson J,Bengtsson U, Zolubas M. Self-reported foodhypersensitivity in Sweden, Denmark, Estonia,Lithuania, and Russia. J Investig Allergol ClinImmunol. 2004;14(1):70-9.</td><td colspan="1" rowspan="1">Native Apple</td><td colspan="1" rowspan="1">Among 1,139subjects with foodallergies, 45%reported sensitivityto apple</td><td colspan="1" rowspan="1">(not reported)</td></tr><tr><td colspan="1" rowspan="1">Barber D, de la Torre F, Lombardero M, Antepara I,Colas C, et al. Component-resolved diagnosis ofpollen allergy based on skin testing with profilin,polcalcin and lipid transfer protein pan-allergens. ClinExp Allergy. 2009; 39: 1764-73.</td><td colspan="1" rowspan="1">RecombinantMal d 4</td><td colspan="1" rowspan="1">Among patientssuffering frompollinosis, 19%were sensitive torMal d 4</td><td colspan="1" rowspan="1">(not reported)</td></tr><tr><td colspan="1" rowspan="1">Barber D, de la Torre F, Feo F, Florido F, Guardia P,Moreno C, et al. Understanding patient sensitizationprofiles in cmplex pollen areas: a molecularepidemological study. Allergy. 2008;63: 1550-8.</td><td colspan="1" rowspan="1">RecombinantMal d 4</td><td colspan="1" rowspan="1">Among patientssuffering frompollinosis, 15%were sensitive torMal d 4</td><td colspan="1" rowspan="1">(not reported)</td></tr><tr><td colspan="1" rowspan="1">Fernandez-Rivas M, Bolhaar S, Gonzalez-ManceboE, Asero R, van LA, Bohle B, Ma Y. Apple allergyacross Europe: how allergen sensitization profilesdetermine the clinical expression of allergies to plantfoods. J Allergy Clin Immunol. 2006;118(2):481-8.</td><td colspan="1" rowspan="1">RecombinantMal d 4</td><td colspan="1" rowspan="1">(not reported)</td><td colspan="1" rowspan="1">Among 389patients withapple allergy, 10-40% were alsopositive to rMal d4</td></tr></table>

$b$ . Other clinical supportive data (when a. and b. are not applicable): Not applicable.

4. Clinical cut-off: Not applicable.

5. Expected values/Reference range:

Not detected.

Refer to the Hoffman’s ’Standard’ and ‘Extended Standard’ classification system utilizing Class 0 to Class IV cut-offs (see Tables I and II below).

Table-I: The Standard classification system utilizes the following class cutoffs:

<table><tr><td rowspan=1 colspan=1>Class</td><td rowspan=1 colspan=1>kU/L</td><td rowspan=1 colspan=1>Reactivity for Individual/Component Allergen(s)</td></tr><tr><td rowspan=2 colspan=1>0*</td><td rowspan=1 colspan=1>&lt; 0.10</td><td rowspan=1 colspan=1>Absent or ND†</td></tr><tr><td rowspan=1 colspan=1>0.10 - 0.34</td><td rowspan=1 colspan=1>Very Low</td></tr><tr><td rowspan=1 colspan=1>I</td><td rowspan=1 colspan=1>0.35 - 0.69</td><td rowspan=1 colspan=1>Low</td></tr><tr><td rowspan=1 colspan=1>I</td><td rowspan=1 colspan=1>0.70 - 3.49</td><td rowspan=1 colspan=1>Moderate</td></tr><tr><td rowspan=1 colspan=1>III</td><td rowspan=1 colspan=1>3.50 - 17.49</td><td rowspan=1 colspan=1>High</td></tr><tr><td rowspan=1 colspan=1>IV</td><td rowspan=1 colspan=1>17.5 - 52.49</td><td rowspan=3 colspan=1>Very High</td></tr><tr><td rowspan=1 colspan=1>V</td><td rowspan=1 colspan=1>52.5  99.99</td></tr><tr><td rowspan=1 colspan=1>VI</td><td rowspan=1 colspan=1>≥ 100</td></tr></table>

\* Class 0 in the standard system signifies: not detectable by second-generation assays. ${ } ^ { \dag } \mathrm { N D }$ : not detectable by IMMULITE 2000 3gAllergy.

Table-II: The Extended standard classification system utilizes the following class cutoffs.   

<table><tr><td rowspan=1 colspan=1>Class</td><td rowspan=1 colspan=1>kU/L</td><td rowspan=1 colspan=1>Reactivity for Individual/Component Allergen(s)</td></tr><tr><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>&lt; 0.10</td><td rowspan=1 colspan=1>Absent or ND</td></tr><tr><td rowspan=1 colspan=1>0/1</td><td rowspan=1 colspan=1>0.10 - 0.24</td><td rowspan=1 colspan=1>Very Low</td></tr><tr><td rowspan=1 colspan=1>I</td><td rowspan=1 colspan=1>0.25 - 0.39</td><td rowspan=1 colspan=1>Low</td></tr><tr><td rowspan=1 colspan=1>I</td><td rowspan=1 colspan=1>0.40 - 1.29</td><td rowspan=1 colspan=1>Moderate</td></tr><tr><td rowspan=1 colspan=1>III</td><td rowspan=1 colspan=1>1.30 - 3.89</td><td rowspan=1 colspan=1>High</td></tr><tr><td rowspan=1 colspan=1>IV</td><td rowspan=1 colspan=1>3.9014.99</td><td rowspan=3 colspan=1>Very High</td></tr><tr><td rowspan=1 colspan=1>V</td><td rowspan=1 colspan=1>15.00 24.99</td></tr><tr><td rowspan=1 colspan=1>VI</td><td rowspan=1 colspan=1>≥ 25</td></tr></table>

† ND: not detectable by IMMULITE 2000 3gAllergy

The choice of classification systems can be made by the user within the IMMULITE 2000 operational software.

Reference: Hoffman, DR. Comparison of methods of performing the Radioallergosorbent test: Phadebas, Fadal-Nalebuff and Hoffman protocols. Ann Allergy. 1980 Dec; 45(6)

# N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.